Lead-212 (Pb-212) Targeted Alpha Therapy Market
完整報告名稱與涵蓋範圍
Lead-212 (Pb-212) Targeted Alpha Therapy Market Size, Share & Trends Analysis Report, By Component (Pb-212 Isotope Supply and Generators, Pb-212 Radioligand Therapeutics (Pipeline and Commercial), Radiochemistry and Manufacturing Services), By Target Indication (Neuroendocrine Tumors, Prostate Cancer, Breast and Other Solid Tumors, Hematologic Malignancies), By End User (Radiopharmaceutical Developers, Hospitals and Cancer Centers, Contract Manufacturers and Radiopharmacies), By Region, and Segment Forecasts, 2026-2035
報告摘要
The lead-212 targeted alpha therapy market covers Pb-212 isotope production and generator systems, the radioligand therapies that use Pb-212 as an in-situ generator of the alpha emitter bismuth-212, and the radiochemistry and manufacturing services surrounding them. The scope distinguishes commercial isotope and generator revenue, which exists today, from therapeutic product revenue, which is forecast from the expected approval timing of late-stage programs rather than assumed as established sales.
The modality is attracting investment because the roughly 10.6-hour half-life of Pb-212 matches the pharmacokinetics of peptides and small ligands, and because thorium-228 and radium-224 generator routes offer a scalable supply path that does not depend on the constrained actinium-225 stockpile. Sponsors are advancing somatostatin-receptor, PSMA and other targeted programs through pivotal trials, while producers build regional generator networks and in-hospital elution models that allow doses to be prepared close to the patient. Alliance activity between large pharmaceutical companies and isotope specialists, together with dedicated alpha-therapy manufacturing capacity, is defining the emerging commercial structure.
Activity is concentrated in the United States and France, with Australian and German producers adding generator capacity and clinical sites expanding across Europe and Asia Pacific. The competitive field is small and specialised, combining vertically integrated isotope-plus-therapeutic developers with pure-play supply companies and radiopharmacy partners.
The InsightAce study provides US$ revenue forecasts for every component, target indication and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lead-212 (Pb-212) Targeted Alpha Therapy Market Snapshot
Chapter 4. Global Lead-212 (Pb-212) Targeted Alpha Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Component Estimates & Trend Analysis
5.1. Component & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Component:
5.2.1. Pb-212 Isotope Supply and Generators
5.2.2. Pb-212 Radioligand Therapeutics (Pipeline and Commercial)
5.2.3. Radiochemistry and Manufacturing Services
Chapter 6. Market Segmentation 2: By Target Indication Estimates & Trend Analysis
6.1. Target Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Target Indication:
6.2.1. Neuroendocrine Tumors
6.2.2. Prostate Cancer
6.2.3. Breast and Other Solid Tumors
6.2.4. Hematologic Malignancies
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Radiopharmaceutical Developers
7.2.2. Hospitals and Cancer Centers
7.2.3. Contract Manufacturers and Radiopharmacies
Chapter 8. Lead-212 (Pb-212) Targeted Alpha Therapy Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Orano Med
10.2. Perspective Therapeutics, Inc.
10.3. ARTBIO
10.4. AdvanCell Isotopes Pty Ltd.
10.5. RadioMedix, Inc.
10.6. Sanofi
10.7. Lantheus Holdings, Inc.
10.8. Alpha-9 Oncology Inc.
10.9. Eckert & Ziegler SE
10.10. PharmaLogic Holdings Corp.
10.11. Nusano, Inc.
10.12. Curium
圖表清單 List of Tables & Figures
Table 1. Global Lead-212 (Pb-212) Targeted Alpha Therapy Revenue Forecast by Component, 2026-2035 (US$ Mn)
Figure 1. Global Lead-212 (Pb-212) Targeted Alpha Therapy Market Snapshot, 2026 & 2035
Table 2. Global Lead-212 (Pb-212) Targeted Alpha Therapy Revenue Forecast by Target Indication, 2026-2035 (US$ Mn)
Figure 2. Global Lead-212 (Pb-212) Targeted Alpha Therapy Market Share by Target Indication, 2026 & 2035
Table 3. Global Lead-212 (Pb-212) Targeted Alpha Therapy Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Pb-212 Generator Supply Routes and Regional Production Network
Table 4. North America Lead-212 (Pb-212) Targeted Alpha Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Late-Stage Pb-212 Radioligand Pipeline and Expected Commercialization Timeline
Table 5. Europe Lead-212 (Pb-212) Targeted Alpha Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Lead-212 (Pb-212) Targeted Alpha Therapy Growth Opportunity Analysis
Table 6. Asia Pacific Lead-212 (Pb-212) Targeted Alpha Therapy Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Alpha Therapy Isotope Comparison: Pb-212 Versus Ac-225 and Th-227
Table 7. Latin America and Middle East & Africa Lead-212 (Pb-212) Targeted Alpha Therapy Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Lead-212 (Pb-212) Targeted Alpha Therapy Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們